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Abstract
Clostridium difficile infection should always be included in the differential diagnosis of patients with
refractory inflammatory bowel disease (IBD) symptoms, as it is well known to induce or mimic a flare
of IBD. There is currently an alarming increase in the incidence of C. difficile infection in Europe and
North America. Current epidemiologic data suggest that more virulent strains, such as C. difficile 027/
NAP1/BI, are emerging. Testing for both C. difficile toxins A and B should be done, and often serial
stool samples may be required, especially if the index of suspicion is high. Patients with IBD do not
necessarily require a history of antibiotic use or hospitalization to acquire the infection and most do
not have pseudomembranes on sigmoidoscopy. C. difficile infection is associated with longer hospital
stays, increased mortality, and higher complication rates, including colectomy. Treatment with oral
vancomycin is probably the drug of choice as one study suggests that patients had lower colectomy
rates on this drug. Further work is required to clarify the best management strategies for C. difficile in
IBD patients, and more effort is needed to halt the rising incidence of this infection, perhaps with
adherence to safer antibiotic prescribing guidelines, hand washing, and cleaner hospital environments,
which should reduce the risk of acquiring and spreading this preventable infection.
Introduction and context
infection and inflammatory
bowel disease
Clostridium difficile infection has gained recent attention
because of its rising incidence in hospitalized patients. C.
difficile complicates the management of inflammatory
bowel disease (IBD) and often can be overlooked in a
patient who presents with an exacerbation of symptoms.
The dilemma facing physicians is when, how often, and
in whom to order expensive stool tests for C. difficile. The
other issue is how to differentiate faecal carriage of C.
difficile from an infection in patients with IBD. The
association of C. difficile with IBD is neither novel nor
recent. In a series of case reports in the early 1980s,
LaMont and Trnka [1] identified an association between
the presence of C. difficile toxin and IBD exacerbation.
Subsequently, a prospective study by the same
investigators showed that C. difficile toxin was found in
the stool of 19% of IBD patients, suggesting that C.
difficile can cause worsening of disease activity in patients
with IBD [2]. In that study, C. difficile was not necessarily
associated with antibiotic use. In contrast, a second
group of investigators found that C. difficile toxin was
present mostly in the stool of IBD patients exposed to
antibiotics, and concluded that there was no association
with IBD activity [3]. More recently, Meyer and
colleagues [4] showed that 20% of patients with IBD
who relapsed had a positive stool test for C. difficile toxin.
C. difficile was observed in 10 of 12 patients whose stool
specimens were positive for any pathogen, all 10 of
whom improved clinically with treatment for C. difficile.
Furthermore, antibiotic use was associated with 90% of
the patients who tested positive for C. difficile [4].
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incidence of C. difficile infections in hospitalized patients
in North America [5,6] and Europe [6] noted mostly
since the turn of this century. Data from US hospital
discharges have revealed a doubling of C. difficile-
associated disease (CDAD) between 1996 and 2003
[7], and the proportion of patients diagnosed with C.
difficile increased by 26% from 2000 to 2001 in non-
federal US hospitals [8]. Patients recently treated with
broad-spectrum antibiotics, hospitalized patients,
immunocompromised individuals, the elderly, and
patients with cancer are all at increased risk for CDAD.
IBD patients are frequently on long-term immunosup-
pressants, are more likely to be hospitalized, often
require antibiotics, and have many of the risk factors
for acquiring CDAD. This brief report will look at the
impact of rising C. difficile rates on the IBD population
and the implications for the clinical management of
these patients in this era of epidemic rates of C. difficile
infections.
Recent advances
C. difficile is an escalating problem in IBD patients
Data from two tertiary referral centres from the US
showed that the incidence of CDAD has not only risen
among hospitalized patients, but was disproportionately
higher in those with IBD [9,10]. A study from St Louis,
Missouri, examined all admissions to a tertiary medical
centre from 1998 to 2004 and found that the incidence
of C. difficile infection had increased among both IBD
and non-IBD patients, with the greatest increase occur-
ring among those with ulcerative colitis (UC) [10]. The
odds ratio for CDAD in Crohn’s disease (CD) was 2.1
[95% confidence interval (CI) 1.3 to 3.4], and the odds
ratio for CDAD in UC was 4.0 (95% CI 2.4 to 6.6). The
median numbers of days from admission to acquiring
CDAD were 0.5 days for UC, 0.8 days for CD, and 4.0
days for all non-IBD diagnoses. While 63% of IBD
patients who acquired CDAD did so within 48 hours of
admission, 63% of non-IBD patients did so only after 48
hours [10].
Another study, from Milwaukee, Wisconsin, reviewed
data from all patients who were followed at this tertiary
IBD centre between 2000 and 2005 [9]. During the last 2
years of the study, the incidence of C. difficile infection
rose from 1.8 to 4.6%. The proportions of IBD patients
within the total number of patients diagnosed with
CDAD were 4% in 2003, 7% in 2004, and 16% in 2005.
Of these, 76% of individuals with IBD contracted CDAD
as an outpatient and 61% of IBD patients with C. difficile
infection had prior antibiotic exposure (most com-
monly, ciprofloxacin). Community-acquired CDAD
occurred three times as often as nosocomial disease.
None of the IBD patients with CDAD had pseudomem-
branes [9]. Also, data from Leuven, Belgium, have shown
a 3.75-fold increase in CDAD between January 2000 and
January 2008 [11]. Considerably fewer IBD patients
(42%) had been noted to have taken prior antibiotics
compared with non-IBD patients (69%).
infection on IBD outcomes
In the Milwaukee study, more than 50% of patients with
IBD and C. difficile required hospitalization and 20% of
hospitalized IBD patients with CDAD required colect-
omy. Immunosuppression and colonic involvement
were independent risk factors for CDAD in IBD [9].
Furthermore, US data from the Nationwide Inpatient
Sample (2003) suggested that patients with C. difficile
and IBD had four times the mortality of those admitted
with IBD alone [adjusted odds ratio (aOR) 4.7, 95% CI
2.9 to 7.9] and twice the mortality of those admitted with
C. difficile but not IBD (aOR 2.2, 95% CI 1.4 to 3.4) [12].
IBD patients with C. difficile also stayed in hospital
longer by an average of 3 days (95% CI 2.3 to 3.7 days).
Intriguingly, the clinical outcomes in the study from
Leuven were better, with IBD patients having a shorter
duration of hospitalization and with only one patient
with UC needing a colectomy [11]. Similarly, the
St Louis, Missouri group also noted no differences in
length of stay between CDAD patients with IBD and
those without IBD [10].
infection in IBD
Several factors may underlie the increasing incidence of
C. difficile among patients with IBD. Increased awareness
among physicians, more sensitive enzyme-linked immu-
nosorbent assay tests for detection of the toxin in stool
samples, and a serendipitous rise unrelated to IBD in
hospitalized patients have all been put forward as
explanations. However, there seem to be many differ-
ences between IBD patients infected with C. difficile
compared with others. The first is that a relatively larger
number of IBD patients have community-acquired
infections [9,10]. Second, fewer IBD patients have had
prior antibiotic use [9–11]. Third, none of the patients
with IBD appear to have developed pseudomembranes
[9,13]. The absence of pseudomembranes can be
attributed to immunosuppression, as studies suggest
that patients with bone marrow or stem cell transplants
on immunosuppression, and those with UC on steroids,
did not develop pseudomembranes with C. difficile
infection [13]. Finally, there have been increasing reports
of C. difficile
total colectomy [14], or even, rarely, many years
following a protocolectomy, usually presenting as
increased ileostomy output or prolonged ileus [15].
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Impact ofC. difficile
Unusual aspects ofC. difficile
enteritis complications in patients after
recentWhile C. difficile enteritis is unusual, it may not be
surprising as early studies involving autopsies [16] and
jejunal aspirates [17] have suggested that the small
bowel may in fact be the reservoir for C. difficile in
humans.
There is considerable debate on whether C. difficile is just
a colonizer in most patients with IBD or whether the
infection does indeed cause an infective colitis super-
imposed on IBD. An intriguing report from Southern
India (where C. difficile infection is still an uncommon
cause of antibiotic-associated diarrhoea) using quantita-
tive polymerase chain reaction (PCR) of species-specific
16s rDNA of C. difficile detected C. difficile in 34 of 37 UC
patients and 20 of 36 healthy volunteers [18]. However,
there were significantly higher numbers of C. difficile in
UC patients but only eight UC and two healthy
volunteers were toxin-positive as well. None of the
patients had received antibiotics for at least 2 months
prior to the study, and none of the patients were treated
for C. difficile infection with no adverse events [18]. This
suggests that there is an overgrowth of C. difficile in UC
patients in India detected by PCR, but the clinical
significance is uncertain.
Implications for clinical practice
Top tips for management
1. Always think C. difficile . Have a high index of suspicion
for C. difficile in symptomatic IBD patients. Patients with
unusual symptoms like watery rather than bloody
diarrhoea in combination with colonic IBD, fever, non-
resolving symptoms with standard treatment, and the
presence of risk factors like recent antibiotic use or
patients on maintenance immunosuppression should
have their stool checked for C. difficile and treated if
positive.
2.
samples may be needed to confirm the diagnosis.
Ninety-two percent of patients were detected by the
fourth sample in the Milwaukee study, and in one
patient the diagnosis was made on only the eighth
sample [9].
3.
IBD, it would be difficult to grade the severity of the C.
difficile colitis but it would be prudent to treat these
patients as if they had severe CDAD. The Milwaukee
experience suggests a high rate of failure with metroni-
dazole and a lower rate of colectomy with oral
vancomycin, therefore oral vancomycin should be the
preferred drug of choice [9].
4. C. difficile in patients
with prolonged ileus post-colectomy for IBD or
increased ileostomy outputs. Chronic pouchitis has
also been attributed to C. difficile in patients with ileo
anal pouch anastomosis [19].
5. C. difficile and IBD
has been associated with higher mortality, higher
colectomy rates, and longer hospitalization. We, as the
medical fraternity, have a responsibility to our patients
and should not be lax in adhering to safe antibiotic
prescribing guidelines or in implementing simple
measures like hand washing between patients to reduce
the spread of this infection.
Future directions
Randomized controlled trials are needed to clarify the
best management strategy for concomitant C. difficile in
IBD patients. What dose of vancomycin should be used?
Would a tapering schedule of vancomycin help prevent
relapse? Are probiotics of any use to prevent or treat this
infection in IBD patients? How does one differentiate
colonization from infection in patients with already
diseased colons? Finally, as already mentioned, a
concerted effort is needed to reduce the rising tide of C.
difficile worldwide with greater emphasis on safer
antibiotic prescribing guidelines, hand washing, cleaner
hospital environments, and greater physician and com-
munity awareness. Until this epidemic is controlled, we
will always have tough questions to answer in the
management of these seriously ill patients on a daily
basis.
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